AGIOS PHARMACEUTICALS, INC.
AGIONasdaq
$39.61
↑ +2.3%Jul 17 close · end-of-day
Price
1Y↓ -1.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.3B
Enterprise Value
$1.6B
P/E
—
P/S
35.3
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
-16.5%
Dividend Yield
—
Revenue (TTM)
$66.0M
Net Income (TTM)
-$422.8M
Free Cash Flow (TTM)
-$384.7M
Gross Margin
—
Operating Margin
-720.0%
Net Margin
-640.2%
ROE
-38.1%
ROIC
-101.0%
Debt / Equity
—
Net Cash
$737.0M
Return 1Y
-1.8%
Company profile
Agios Pharmaceuticals, Inc. engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes. AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.
- CEO
- Brian M. Goff
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 390
- Headquarters
- Massachusetts
- Website
- agios.com
Management & directors
- Gheuens SarahChief Medical Officer
- Burns James WilliamChief Legal Officer
- Goff BrianChief Executive Officer
- Jones CeciliaChief Financial Officer
- Milanova TsvetaChief Commercial Officer
- Viswanadhan KrishnanChief Corp Dev & Strategy
- Washburn Theodore James Jr.Principal Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
AGIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$20.7M↑ +137.7%
Diluted EPS-$1.69↑ +9.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $14.2M | $26.8M | $36.5M | $54.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$335.9M | -$378.4M | -$389.0M | -$391.5M | -$425.7M | -$472.1M |
| Net income | -$327.4M | $1.6B | -$232.0M | -$352.0M | $674.0M | -$413.0M |
| Diluted EPS | -$4.74 | $26.55 | -$4.23 | -$6.33 | $11.64 | -$7.12 |
| Operating cash flow | -$290.8M | -$407.3M | -$309.5M | -$296.1M | -$389.8M | -$373.0M |
| Free cash flow | -$304.9M | -$413.1M | -$314.4M | -$297.1M | -$391.5M | -$377.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | -2732.1% | -1459.5% | -1166.5% | -873.9% |
| Net margin | — | — | -1629.2% | -1312.3% | 1846.7% | -764.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.6M | $9.0M | $10.7M | $8.7M | $12.5M | $12.9M | $20.0M | $20.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$105.8M | -$102.8M | -$125.0M | -$106.6M | -$127.1M | -$116.9M | -$121.6M | -$110.0M |
| Net income | -$96.1M | $947.9M | -$96.2M | -$89.3M | -$112.0M | -$103.4M | -$108.3M | -$99.1M |
| Diluted EPS | -$1.69 | $16.22 | -$1.44 | -$1.55 | -$1.93 | -$1.78 | -$1.86 | -$1.69 |
| Operating cash flow | -$72.6M | -$84.2M | -$133.2M | -$111.5M | -$77.1M | -$88.2M | -$96.2M | -$118.9M |
| Free cash flow | -$72.7M | -$84.6M | -$134.1M | -$112.3M | -$78.0M | -$89.7M | -$97.3M | -$119.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1228.3% | -1146.9% | -1165.3% | -1222.0% | -1020.1% | -907.4% | -608.9% | -530.3% |
| Net margin | -1115.7% | 10574.7% | -897.0% | -1023.3% | -899.4% | -803.1% | -542.2% | -477.7% |
Company news
Jul 10, 2026
Jul 9, 2026
Jul 8, 2026
Jul 7, 2026
- 13d agoWhy This Novo Nordisk Rival Just Soared To A Profit-Taking Zonefinance.yahoo.com
- 13d agoHere's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)fool.com
- 13d agoAGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimismstocktwits.com
- 13d agoModerna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Saysfinance.yahoo.com
- 13d agoU.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Diseasefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Backstrom Jay T. | Award | 1,447 | $0.00 | $0.00 | filing |
| 2026-07-01 | Gheuens Sarah· Chief Medical Officer | Sale | 4,007 | $37.56 | $150,502.92 | filing |
| 2026-07-01 | Gheuens Sarah· Chief Medical Officer | Option exercise | 8,375 | $0.00 | $0.00 | filing |
| 2026-06-18 | Foster-Cheek Kaye I | Option exercise | 2,816 | $0.00 | $0.00 | filing |
| 2026-06-18 | FOUSE JACQUALYN A | Option exercise | 2,816 | $0.00 | $0.00 | filing |
| 2026-06-18 | Owen Catherine E. | Option exercise | 2,816 | $0.00 | $0.00 | filing |
| 2026-06-18 | Scadden David | Option exercise | 2,816 | $0.00 | $0.00 | filing |
| 2026-06-18 | Smith Cynthia | Option exercise | 2,816 | $0.00 | $0.00 | filing |
| 2026-06-18 | Ho Maykin | Option exercise | 2,816 | $0.00 | $0.00 | filing |
| 2026-06-18 | Ballal Rahul D. | Option exercise | 2,816 | $0.00 | $0.00 | filing |
| 2026-06-18 | CAPELLO JEFFREY D | Option exercise | 2,816 | $0.00 | $0.00 | filing |
| 2026-06-13 | Owen Catherine E. | Option exercise | 1,976 | $0.00 | $0.00 | filing |
| 2026-06-13 | CAPELLO JEFFREY D | Option exercise | 1,976 | $0.00 | $0.00 | filing |
| 2026-04-02 | Goff Brian· Chief Executive Officer | Sale | 12,472 | $34.71 | $432,903.12 | filing |
| 2026-04-02 | Goff Brian· Chief Executive Officer | Sale | 6,596 | $34.71 | $228,947.16 | filing |
| 2026-04-02 | Burns James William· Chief Legal Officer | Sale | 3,280 | $34.71 | $113,848.80 | filing |
| 2026-04-02 | Milanova Tsveta· Chief Commercial Officer | Sale | 3,262 | $34.71 | $113,224.02 | filing |
| 2026-04-02 | Jones Cecilia· Chief Financial Officer | Sale | 3,141 | $34.71 | $109,024.11 | filing |
| 2026-04-02 | Viswanadhan Krishnan· Chief Corp Dev & Strategy | Sale | 2,959 | $34.71 | $102,706.89 | filing |
| 2026-04-02 | Gheuens Sarah· Chief Medical Officer | Sale | 2,940 | $34.71 | $102,047.40 | filing |
| 2026-04-02 | Goff Brian· Chief Executive Officer | Option exercise | 13,500 | $0.00 | $0.00 | filing |
| 2026-04-02 | Gheuens Sarah· Chief Medical Officer | Option exercise | 8,500 | $0.00 | $0.00 | filing |
| 2026-04-02 | Burns James William· Chief Legal Officer | Option exercise | 8,500 | $0.00 | $0.00 | filing |
| 2026-04-02 | Jones Cecilia· Chief Financial Officer | Option exercise | 8,500 | $0.00 | $0.00 | filing |
| 2026-04-02 | Milanova Tsveta· Chief Commercial Officer | Option exercise | 8,500 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.